Michelle Gaddis
Nurse Practitioner · Medford, NYNPI 1639890858
Payments from drug & device makers
Across 182 payments — averaging $14.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$2K
- Novo Nordisk$206
- Amgen$139
- Corcept Therapeutics$137
- Boehringer Ingelheim$110
- Lilly USA, LLC$71
- plus $188 from 7 others
What the payments were for
- Food & beverage$2,580100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic | 138 | $1,730 |
| Novo Nordisk | 14 | $206 |
| Amgen | 7 | $139 |
| Corcept Therapeutics | 6 | $137 |
| Boehringer Ingelheim | 5 | $110 |
| Lilly USA, LLC | 3 | $71 |
| Xeris Pharmaceuticals, Inc. | 3 | $61 |
| Pfizer | 1 | $30 |
| Abbott | 1 | $24 |
| Chiesi USA, Inc. | 1 | $24 |
| Ascendis Pharma Endocrinology Inc | 1 | $21 |
| Amneal Pharmaceuticals LLC | 1 | $15 |
| Stryker | 1 | $14 |
How this compares
$2,580 in reported general payments places this provider in the 90th percentile of 4,112 nurse practitioner providers in New York.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 99 | $194,787 |
| MounjaroTirzepatide | 81 | $163,510 |
| JardianceEmpagliflozin | 105 | $126,254 |
| TrulicityDulaglutide | 52 | $87,295 |
| RybelsusSemaglutide | 34 | $49,476 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 13 | $16,885 |
| FarxigaDapagliflozin Propanediol | 14 | $14,328 |
| TradjentaLinagliptin | 13 | $9,583 |
| Metformin Hcl ErMetformin Hcl | 240 | $4,047 |
| SynthroidLevothyroxine Sodium | 32 | $2,783 |
| Novolog FlexpenInsulin Aspart | 11 | $2,284 |
| Levothyroxine Sodium | 126 | $1,976 |
| Nano 2nd Gen Pen NeedlePen Needle, Diabetic | 17 | $1,705 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 15 | $1,677 |
| Nateglinide | 13 | $690 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $71 | $250,805133 claims |
| Novo NordiskOzempic, Rybelsus | $206 | $244,262133 claims |
| Boehringer IngelheimJardiance, Synjardy Xr, Tradjenta | $110 | $152,722131 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $15 | $1,976126 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,112 nurse practitioner providers in New York.
Other nurse practitioner in Medford
- Patricia McGoldrickNew York$202K
- Michelle DartSyracuse$95K
- Susan KreppelWilliamsville$67K
- Kerry AhernEast Syracuse$55K
- Valerie StanleyAlbany$55K
- Jodi LogerfoNew York$48K
- Grace WlasowiczRochester$41K
- Melissa LevinElmhurst$34K
- Carla JungquistCanandaigua$28K
- Kelly WilmarthJohnson City$26K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.